TARGET Intracranial Aneurysm Coiling Registry
Launched by MERCY HEALTH OHIO · Dec 12, 2012
Trial Information
Current as of June 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient is 18 years or older.
- • 2. Patient has a documented, previously untreated, saccular intracranial aneurysm, unruptured or ruptured, suitable for embolization with coils.
- • 3. (NEW NANO arm ONLY) Target aneurysm is ≤7mm.
- • 4. Patient has a Hunt and Hess Score of 3 or less.
- • 5. Patient has a premorbid mRS of 3 or less.
- • 6. Patient or patient's legally authorized representative has provided written informed consent.
- • 7. Patient is willing to and can comply with study follow-up requirements.
- Exclusion Criteria:
- • 1. Patient is \< 18 years old.
- • 2. Dissecting aneurysm.
- • 3. Patients with intracranial aneurysms (other than the target aneurysm) that will require treatment during the study period (enrollment through follow-up).
- • 4. Patients in whom the target aneurysm will be treated with coils other than Stryker Target® 360°, Target® Helical coils, and 2nd generation Target® Nano Coils.
- • 5. (NEW NANO Arm ONLY) Patients in whom the target aneurysm was treated with a total coil length comprised of \<25% Stryker Target® 2nd generation Nano Coils.
- • 6. Target aneurysm is fusiform.
- • 7. Patients in which the target aneurysm cannot be coiled in one procedure (i.e. staged procedure)
About Mercy Health Ohio
Mercy Health Ohio is a leading healthcare provider dedicated to delivering high-quality, patient-centered care across the region. As a prominent sponsor of clinical trials, Mercy Health Ohio focuses on advancing medical research and innovation to improve health outcomes for diverse populations. With a commitment to ethical practices and rigorous scientific standards, the organization collaborates with healthcare professionals and researchers to develop and implement clinical studies that explore new treatments, therapies, and technologies. By fostering a culture of excellence in research, Mercy Health Ohio aims to contribute significantly to the advancement of medical knowledge and enhance the overall health of the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Worcester, Massachusetts, United States
Tallahassee, Florida, United States
Joliet, Illinois, United States
Greenville, South Carolina, United States
Phoenix, Arizona, United States
Flint, Michigan, United States
Saint Louis, Missouri, United States
Toledo, Ohio, United States
Morgantown, West Virginia, United States
Patients applied
Trial Officials
Osama O Zaidat, MD, MS
Principal Investigator
Mercy Health St. Vincent Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials